Paolo Ghia, MD, PhD, on CLL/SLL and Ibrutinib Plus Venetoclax: A Primary Analysis of the CAPTIVATE Trial

June 22, 2021 By The ASCO Post Staff

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses phase II results from the CAPTIVATE study, which examined ibrutinib plus venetoclax as a fixed-duration first-line treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7501).

Related Content